An observational study in Endometrial Cancer, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by National Institute of Cancerología · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Endometrial Neoplasms with a site in Mexico — 4 open to participants now, 7 under way, 4 of them phase 3. Endometrial Neoplasms · Mexico.
Among the 10 studies in Endometrial Neoplasms with a site in Mexico, this one is one of 2 that started in 2024, is the only observational one, and was the 7th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →4 of the 10 studies in Endometrial Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Mexico, United States, Argentina and 31 more countries
Ages 18+ · Women only
National Institute of Cancerología · Sites in Mexico
Ages 18–65 · Women only
Daiichi Sankyo · Sites in Mexico, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Median enrollment 805 across the 9 interventional studies, 64 across the 1 observational. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 6 most frequent:
National Institute of Cancerología is the lead sponsor of 39 studies on the registry; 10 are open to participants now.
National Institute of Cancerología has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Endometrial Neoplasms with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07025213National Institute of CancerologíaMetabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery. | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Endometrial Neoplasms with a site in Mexico, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.
The investigators will carry out a pilot study on patients with endometrioid type EC treated between 2015-2019. Samples of patients over 18 years of age admitted to the cohort with a diagnosis of endometrioid-type EC are already collected and will be evaluated for exome sequencing (N=32) and the detection of POLE mutations. DNA will be extracted using the "DNA/RNA AllPrep" kit (QIAGEN). Verification of adequate DNA extraction will be performed by quantifying using TapeStation (Agilent). Exome sequencing (N = 32 tumor samples and 32 somatic samples [leukocytes] from the same patient) will be carried out using Illumina's Nextera Rapid Capture Exome at Azenta Life Science (NJ, USA) following preset protocols and with a depth of 100X. The alignment and detection of variants will be done with the GATX-Mutect Suite (Broad Institute, USA) and the annotation of variant filtering with ANNOVAR. The identification of hotspots will be made according to Chen study. The immunohistochemistry (IHC) for microsatellite instability and overexpressed mutant TP53 (N = 94) will be done using established IHC protocols and will include MSH2, MLH1, PMS1, PMS2, MSH6, MSH3, and TP53.
The investigators will evaluate samples from patients with endometrioid type EC treated between 2015-2019. Samples of patients over 18 years of age admitted to the cohort with a diagnosis of endometrioid-type EC are already collected and will be evaluated for exome sequencing (N=32) for the detection of POLE mutations.
Criteria: Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.
Genetic: Descriptive and analytical
Patients with EC endometroid
sequence the exome
Molecular classification of endometroid-type endometrial cancer in Mexican participants based on POLE and TP53 mutations as well as makers of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3).
Time frame: 2024-2025
Determine POLE mutations
Determine POLE mutations by massive next-generation sequencing of a discovery cohort in patients with endometroid-type EC.
Time frame: 2024-2025
Determine microsatellite instability
To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.
Time frame: 2025-2026
Validation
To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.
Time frame: 2025-2026
Overall survival
To describe the overall survival of molecular types of endometroid-type EC in INCan patients.
Time frame: 2025-2026
Disease-free surviva
To describe the disease-free survival of the molecular types of endometroid-type EC in INCan patients.
Time frame: 2025-2026
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Any time by direct request to the principal investigator
Access criteria: Only for research purposes.
No publications or documents are linked to this record.
Start is estimated for Mar 2024; primary completion for Nov 2026, 32 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cancerología